

## VI-2. データ利用一元化以前の論文業績

\*原著論文。一元化登録以前の業績。

\*複数のレジストリにまたがる合同の論文は、論文数が重複しないよう、いずれか一つのレジストリのみ記載されています。

### VI-2-1. 日本造血細胞移植学会 論文業績

---

A1. Matsuo K, Hamajima N, Morishima Y, Harada M.

Hospital capacity and post-transplant survival after allogeneic bone marrow transplantation: analysis of data from the Japan Society for Hematopoietic Cell Transplantation.

*Bone Marrow Transplant.* 2000;26(10):1061-7.

A2. Tamaki S, Ichinohe T, Matsuo K, Hamajima N, Hirabayashi N, Dohy H; Japan Society of Hematopoietic Cell Transplantation.

Superior survival of blood and marrow stem cell recipients given maternal grafts over recipients given paternal grafts.

*Bone Marrow Transplant.* 2001;28(4):375-80.

A3. Kanda Y, Chiba S, Hirai H, Sakamaki H, Iseki T, Kodera Y, Karasuno T, Okamoto S, Hirabayashi N, Iwato K, Maruta A, Fujimori Y, Furukawa T, Mineishi S, Matsuo K, Hamajima N, Imamura M.

Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000).

*Blood.* 2003;102(4):1541-7.

A4. Kataoka I, Kami M, Takahashi S, Kodera Y, Miyawaki S, Hirabayashi N, Okamoto S, Matsumoto N, Miyazaki Y, Morishita Y, Asai O, Maruta A, Yoshida T, Imamura M, Hamajima N, Matsuo K, Harada M, Mineishi S; Japan Society for Hematopoietic Cell Transplantation Working Party.

Clinical impact of graft-versus-host disease against leukemias not in remission at the time of allogeneic hematopoietic stem cell transplantation from related donors. The Japan Society for Hematopoietic Cell Transplantation Working Party.

*Bone Marrow Transplant.* 2004;34(8):711-9.

A5. Kanda Y, Izutsu K, Hirai H, Sakamaki H, Iseki T, Kodera Y, Okamoto S, Mitsui H, Iwato K, Hirabayashi N, Furukawa T, Maruta A, Kasai M, Atsuta Y, Hamajima N, Hiraoka A, Kawa K.

Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate.

*Leukemia.* 2004;18(5):1013-9.

A6. Ogawa H, Ikegame K, Kawakami M, Takahashi S, Sakamaki H, Karasuno T, Sao H, Kodera Y, Hirabayashi N, Okamoto S, Harada M, Iwato K, Maruta A, Tanimoto M, Kawa K; Japan Society for Hematopoietic Cell Transplantation.

Impact of cytogenetics on outcome of stem cell transplantation for acute myeloid leukemia in first remission: a large-scale retrospective analysis of data from the Japan Society for Hematopoietic Cell Transplantation.

*Int J Hematol.* 2004;79(5):495-500.

- A7. Yanada M, Emi N, Naoe T, Sakamaki H, Iseki T, Hirabayashi N, Karasuno T, Chiba S, Atsuta Y, Hamajima N, Takahashi S, Kato S.  
Allogeneic myeloablative transplantation for patients aged 50 years and over.  
*Bone Marrow Transplant.* 2004;34(1):29-35.
- A8. Yanada M, Emi N, Naoe T, Sakamaki H, Takahashi S, Hirabayashi N, Hiraoka A, Kanda Y, Tanosaki R, Okamoto S, Iwato K, Atsuta Y, Hamajima N, Tanimoto M, Kato S.  
Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan.  
*Bone Marrow Transplant.* 2004;34(4):331-7.
- A9. Nakai K, Kanda Y, Fukuhara S, Sakamaki H, Okamoto S, Kodera Y, Tanosaki R, Takahashi S, Matsushima T, Atsuta Y, Hamajima N, Kasai M, Kato S.  
Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome.  
*Leukemia.* 2005;19(3):396-401.
- A10. Yanada M, Naoe T, Iida H, Sakamaki H, Sakura T, Kanamori H, Kodera Y, Okamoto S, Kanda Y, Sao H, Asai O, Nakai K, Maruta A, Kishi K, Furukawa T, Atsuta Y, Yamamoto K, Tanaka J, Takahashi S.  
Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease.  
*Bone Marrow Transplant.* 2005;36(10):867-72.
- A11. Imamura M, Asano S, Harada M, Ikeda Y, Kato K, Kato S, Kawa K, Kojima S, Morishima Y, Morishita Y, Nakahata T, Okamura J, Okamoto S, Shiobara S, Tanimoto M, Tsuchida M, Atsuta Y, Yamamoto K, Tanaka J, Hamajima N, Kodera Y.  
Current status of hematopoietic cell transplantation for adult patients with hematologic diseases and solid tumors in Japan.  
*Int J Hematol.* 2006;83(2):164-78.
- A12. Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, Kato K, Tabuchi K, Tsuchida M, Morishima Y, Mitamura M, Kawa K, Kato S, Nagamura T, Takanashi M, Kodera Y.  
Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System.  
*Int J Hematol.* 2007;86(3):269-74.
- A13. 熱田由子、鈴木律朗、吉見礼美、権藤久司、田中淳司、平岡諦、加藤剛二、田渕健、土田昌宏、森島泰雄、三田村真、河敬世、加藤俊一、長村登紀子、高梨美乃子、小寺良尚。  
本邦における造血細胞移植登録の一元化と「移植登録一元管理プログラム (TRUMP)」の作成。  
*臨床血液.*2007;48(11):1462-9.

- A14. Kuwatsuka Y, Miyamura K, Suzuki R, Kasai M, Maruta A, Ogawa H, Tanosaki R, Takahashi S, Koda K, Yago K, Atsuta Y, Yoshida T, Sakamaki H, Koder Y.  
Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes.  
*Blood.* 2009;113(9):2096-103.
- A15. Nagafuji K, Matsuo K, Teshima T, Mori S, Sakamaki H, Hidaka M, Ogawa H, Koder Y, Kanda Y, Maruta A, Mori T, Yoshida F, Ichinohe T, Kasai M, Takatsuka Y, Kubo K, Sao H, Atsuta Y, Suzuki R, Yoshida T, Tsuchida M, Harada M.  
Peripheral blood stem cell versus bone marrow transplantation from HLA-identical sibling donors in patients with leukemia: a propensity score-based comparison from the Japan Society for Hematopoietic Stem Cell Transplantation registry.  
*Int J Hematol.* 2010;91(5):855-64.
- A16. Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, Tanosaki R, Kawano F, Miyazaki Y, Masuda M, Nagafuji K, Hara M, Takanashi M, Kai S, Atsuta Y, Suzuki R, Kawase T, Matsuo K, Nagamura-Inoue T, Kato S, Sakamaki H, Morishima Y, Okamura J, Ichinohe T, Uchiyama T.  
Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study.  
*Blood.* 2010;116(8):1369-76.
- A17. Asakura M, Ikegame K, Yoshihara S, Taniguchi S, Mori T, Etoh T, Takami A, Yoshida T, Fukuda T, Hatanaka K, Kanamori H, Yujiri T, Atsuta Y, Sakamaki H, Suzuki R, Ogawa H.  
Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor.  
*Int J Hematol.* 2010;92(2):351-9.
- A18. Nishiwaki S, Inamoto Y, Sakamaki H, Kurokawa M, Iida H, Ogawa H, Fukuda T, Ozawa Y, Kobayashi N, Kasai M, Mori T, Iwato K, Yoshida T, Onizuka M, Kawa K, Morishima Y, Suzuki R, Atsuta Y, Miyamura K.  
Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission.  
*Blood.* 2010;116(20):4368-75.
- A19. Iida M, Fukuda T, Ikegame K, Yoshihara S, Ogawa H, Taniguchi S, Takami A, Abe Y, Hino M, Etou T, Ueda Y, Yujiri T, Matsui T, Okamura A, Tanaka J, Atsuta Y, Koder Y, Suzuki R.  
Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan.  
*Int J Hematol.* 2011;93(4):523-31.

- A20. Shigematsu A, Tanaka J, Suzuki R, Atsuta Y, Kawase T, Ito YM, Yamashita T, Fukuda T, Kumano K, Iwato K, Yoshida F, Kanamori H, Kobayashi N, Fukuhara T, Morishima Y, Imamura M.  
Outcome of medium-dose VP-16/CY/TBI superior to CY/TBI as a conditioning regimen for allogeneic stem cell transplantation in adult patients with acute lymphoblastic leukemia.  
*Int J Hematol.* 2011;94(5):463-71.
- A21. Kako S, Morita S, Sakamaki H, Ogawa H, Fukuda T, Takahashi S, Kanamori H, Onizuka M, Iwato K, Suzuki R, Atsuta Y, Kyo T, Sakura T, Jinnai I, Takeuchi J, Miyazaki Y, Miyawaki S, Ohnishi K, Naoe T, Kanda Y.  
A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission who have an HLA-matched sibling donor.  
*Leukemia.* 2011;25(2):259-65.
- A22. Hatanaka K, Fuji S, Ikegame K, Kato R, Wake A, Hidaka M, Ito T, Inoue M, Nagatoshi Y, Takami A, Uike N, Sakamaki H, Yabe H, Morishima Y, Suzuki R, Atsuta Y, Fukuda T.  
Low incidences of acute and chronic graft-versus-host disease after unrelated bone marrow transplantation with low-dose anti-T lymphocyte globulin.  
*Int J Hematol.* 2012;96(6):773-80.
- A23. Kanda J, Hishizawa M, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, Tanosaki R, Kawano F, Miyazaki Y, Masuda M, Nagafuji K, Hara M, Takanashi M, Kai S, Atsuta Y, Suzuki R, Kawase T, Matsuo K, Nagamura-Inoue T, Kato S, Sakamaki H, Morishima Y, Okamura J, Ichinohe T, Uchiyama T.  
Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study.  
*Blood.* 2012;119(9):2141-8.
- A24. Atsuta Y, Suzuki R, Yamashita T, Fukuda T, Miyamura K, Taniguchi S, Iida H, Uchida T, Ikegame K, Takahashi S, Kato K, Kawa K, Nagamura-Inoue T, Morishima Y, Sakamaki H, Kodaera Y.  
Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease.  
*Ann Oncol.* (in press).